|1.||Yule, Murray: 2 articles (01/2015 - 06/2014)|
|2.||Lyons, John F: 2 articles (01/2015 - 07/2010)|
|3.||Pearson, Andrew D J: 2 articles (01/2015 - 09/2011)|
|4.||Lock, Victoria: 2 articles (01/2015 - 06/2014)|
|5.||Squires, Matt: 2 articles (09/2011 - 05/2011)|
|6.||Moawad, Emad Y: 1 article (12/2015)|
|7.||Rodriguez, Ana: 1 article (01/2015)|
|8.||Makin, Guy: 1 article (01/2015)|
|9.||Ross, Philip: 1 article (01/2015)|
|10.||Acton, Gary: 1 article (01/2015)|
12/01/2013 - "Ongoing AT9283 trials will assess efficacy and safety in solid and haematological cancers."
12/01/2015 - "Dose modeling was performed by analyzing previously published data of AT9283 cancer growth inhibition in vivo. "
01/15/2015 - "AT9283 was well tolerated in children and adolescents with solid tumors with manageable hematologic toxicity. "
06/15/2012 - "AT9283, a pan-aurora inhibitor inhibited growth and survival of multiple solid tumors in vitro and in vivo. "
05/01/2012 - "Patients with advanced tumors received AT9283 as a continuous central venous infusion over 3 days in cohorts of three to six patients starting at 1.5 mg/m(2)/day (equivalent to 4.5 mg/m(2)/72 h). "
07/01/2013 - "It was found that AT9283 significantly inhibited the growth and survival of cell lines derived from patients with pediatric leukemia. "
07/01/2013 - "Based on this premise, we evaluated the activity of the Aurora-A/B inhibitor AT9283 against pediatric leukemia cells. "
06/01/2014 - "This study sought to identify the maximum tolerated dose (MTD) of AT9283, an inhibitor of Aurora kinases A and B, in patients with relapsed or refractory leukemias. "
09/01/2011 - "Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia."
06/01/2014 - "A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis."
|3.||Non-Hodgkin Lymphoma (Lymphosarcoma)
06/15/2012 - "In this study, we demonstrated that AT9283 had potent activity against Aurora B in a variety of aggressive B-(non-Hodgkin lymphoma) B-NHL cell lines. "
12/01/2013 - "Patients with advanced, incurable solid tumors or non-Hodgkin's lymphoma received AT9283 as a continuous 24-hour infusion on days 1, 8 of a 21-day cycle. "
|4.||Primary Myelofibrosis (Myelosclerosis)
05/15/2011 - "In this study, we investigated the preclinical activity of a small-molecule multitargeted kinase inhibitor, AT9283, with potent activity against Aurora kinase A, Aurora kinase B, and Janus kinase 2/3. We evaluated the in vitro antimyeloma activity of AT9283 alone and in combination with lenalidomide and the in vivo efficacy by using a xenograft mouse model of human MM. Our data showed that AT9283 induced cell-growth inhibition and apoptosis in MM. Studying the apoptosis mechanism of AT9283 in MM, we observed features consistent with both Aurora kinase A and Aurora kinase B inhibition, such as increase of cells with polyploid DNA content, decrease in phospho-histone H3, and decrease in phospho-Aurora A. "
|1.||aurora kinase (aurora A kinase)
|3.||Janus Kinase 2
|5.||DNA (Deoxyribonucleic Acid)
|6.||lenalidomide (CC 5013)
|8.||dasatinib (BMS 354825)
|1.||Heterologous Transplantation (Xenotransplantation)